CN114007625A - 用于治疗眼病的化合物和方法 - Google Patents

用于治疗眼病的化合物和方法 Download PDF

Info

Publication number
CN114007625A
CN114007625A CN202080044806.4A CN202080044806A CN114007625A CN 114007625 A CN114007625 A CN 114007625A CN 202080044806 A CN202080044806 A CN 202080044806A CN 114007625 A CN114007625 A CN 114007625A
Authority
CN
China
Prior art keywords
alkyl
compound
optionally substituted
oxy
heteroalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080044806.4A
Other languages
English (en)
Chinese (zh)
Inventor
伊恩·霍尔姆斯
亚伊尔·阿尔斯特
希拉·巴拉什
查尔斯·博斯沃斯
奥默·拉法尔里
马克·格利森
马克·理查德·斯图尔特
乔纳森·杜恩
罗伯特·M·伯克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mg Therapeutics Ltd
Original Assignee
Mg Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mg Therapeutics Ltd filed Critical Mg Therapeutics Ltd
Publication of CN114007625A publication Critical patent/CN114007625A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
CN202080044806.4A 2019-04-18 2020-04-16 用于治疗眼病的化合物和方法 Pending CN114007625A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962835975P 2019-04-18 2019-04-18
US62/835,975 2019-04-18
US202062966482P 2020-01-27 2020-01-27
US62/966,482 2020-01-27
PCT/IB2020/000312 WO2020212760A2 (en) 2019-04-18 2020-04-16 Compounds and methods for the treatment of ocular disorders

Publications (1)

Publication Number Publication Date
CN114007625A true CN114007625A (zh) 2022-02-01

Family

ID=72837068

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080044806.4A Pending CN114007625A (zh) 2019-04-18 2020-04-16 用于治疗眼病的化合物和方法

Country Status (9)

Country Link
US (2) US11643429B2 (cg-RX-API-DMAC10.html)
EP (1) EP3955937A4 (cg-RX-API-DMAC10.html)
JP (2) JP7904691B2 (cg-RX-API-DMAC10.html)
KR (1) KR20210154214A (cg-RX-API-DMAC10.html)
CN (1) CN114007625A (cg-RX-API-DMAC10.html)
AU (1) AU2020259997B2 (cg-RX-API-DMAC10.html)
CA (1) CA3136369A1 (cg-RX-API-DMAC10.html)
IL (1) IL287280A (cg-RX-API-DMAC10.html)
WO (1) WO2020212760A2 (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116940570A (zh) * 2020-10-21 2023-10-24 阿祖拉眼科有限公司 用于治疗眼部病症的化合物和方法

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020212755A1 (en) 2019-04-18 2020-10-22 Azura Ophthalmics Ltd. Compounds and methods for the treatment of ocular disorders
AU2020259997B2 (en) 2019-04-18 2025-08-07 Azura Ophthalmics Ltd. Compounds and methods for the treatment of ocular disorders
EP4087655A4 (en) 2020-01-10 2024-02-21 Azura Ophthalmics Ltd INSTRUCTIONS FOR COMPOSITION AND SENSITIVITY
CA3196145A1 (en) * 2020-10-21 2022-04-28 Azura Ophthalmics Ltd. Compounds and methods for the treatment of ocular disorders
WO2023067387A2 (en) * 2021-10-20 2023-04-27 Azura Ophthalmics Ltd. Compounds and methods for the treatment of dermal and ocular disorders
TW202421700A (zh) 2022-07-28 2024-06-01 日商住友化學股份有限公司 偏光膜的製造方法及製造裝置
WO2024101918A1 (ko) * 2022-11-11 2024-05-16 주식회사 메디치바이오 리포-하이드록삼산 유도체 및 이의 약학적 용도
US20260109705A1 (en) * 2022-12-20 2026-04-23 Azura Ophthalmics Ltd. Compounds and methods for the treatment of ocular disorders
WO2025012700A2 (en) * 2023-07-07 2025-01-16 Azura Ophthalmics Ltd. Compositions and methods for the treatment of autoimmune disorders

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1816557A (zh) * 2003-05-13 2006-08-09 葛兰素集团有限公司 新型14和15元环化合物
CN1820017A (zh) * 2003-05-13 2006-08-16 葛兰素集团有限公司 4"位取代的大环内酯类
CN1837225A (zh) * 2005-08-23 2006-09-27 济南思创生物技术有限公司 阿奇霉素衍生物及其制法和药物应用
CN1852912A (zh) * 2003-05-13 2006-10-25 葛兰素集团有限公司 新型14和15元环化合物
WO2013003731A2 (en) * 2011-06-29 2013-01-03 Insite Vision Incorporated Methods of treating recurrent meibomian glands disorder and thereby decreasing the frequency of recurrence
US20130045938A1 (en) * 2010-02-15 2013-02-21 Synovo Gmbh Kinase modulators for the treatment of cancer
WO2018161039A1 (en) * 2017-03-03 2018-09-07 Synovo Gmbh Novel anti-infective and anti-inflammatory compounds
WO2018215638A1 (en) * 2017-05-26 2018-11-29 Novaliq Gmbh Pharmaceutical compositions comprising azithromycin

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474768A (en) * 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
KR930702369A (ko) * 1990-10-15 1993-09-08 우에노 아키라 에리쓰로마이신 또는 그의 유도체의 2'위치 수식 화합물
WO1995018604A1 (en) * 1994-01-11 1995-07-13 Ciba-Geigy Ag Topical treatment of ocular photophobia
KR100477070B1 (ko) 1994-03-25 2006-04-21 이소테크니카 인코포레이티드 중수소화작용에의한의약품의효능강화법
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
US7056893B2 (en) 1999-03-31 2006-06-06 Insite Vision, Inc. Topical treatment for prevention of ocular infections
US6239113B1 (en) 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
EP1101769A3 (en) * 1999-11-18 2001-10-24 Pfizer Products Inc. Nitrogen containing erythromycin derivatives
CA2445306C (en) * 2001-04-27 2008-02-12 Pfizer Products Inc. Process for preparing 4"-substituted-9-deoxo-9a-aza-9a-homoerythromycin a derivatives
FR2832637B1 (fr) * 2001-06-07 2004-07-30 Lefaix Marie Therese Droy Utilisation d'un antioxydant pour la fabrication d'un medicament destine au traitement des affections oculaires de surface
EP1483277A4 (en) * 2002-02-15 2007-10-03 Merckle Gmbh CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND USE, FORMULATION AND PHARMACEUTICAL APPLICATIONS THEREOF
GB0609373D0 (en) * 2006-05-11 2006-06-21 Glaxo Group Ltd Macrolones
PE20090879A1 (es) * 2007-07-30 2009-07-25 Glaxosmithkline Zagreb DERIVADOS 9-DESOXO-9a-METIL-9a-AZA-9a-HOMOERITROMICINA A COMO AGENTES ANTIMALARICOS
JP2012516305A (ja) * 2009-01-30 2012-07-19 グラクソ グループ リミテッド 好中球優位の炎症性疾患の治療のための9−デオキソ−9a−メチル−9a−アザ−9a−ホモエリスロマイシンa誘導体
EP2831083A4 (en) * 2012-03-27 2016-03-09 Michael W Burnet INFLAMMATORY MAKROLIDE
US9463201B2 (en) 2014-10-19 2016-10-11 M.G. Therapeutics Ltd Compositions and methods for the treatment of meibomian gland dysfunction
CA3020713A1 (en) 2016-04-19 2017-10-26 Azura Ophthalmics Ltd. Compositions for the treatment of hyperkeratosis disorders
CA3057569A1 (en) 2017-03-29 2018-10-04 Azura Ophthalmics Ltd. Agents for increasing meibomian gland lipid secretion
AU2020259997B2 (en) 2019-04-18 2025-08-07 Azura Ophthalmics Ltd. Compounds and methods for the treatment of ocular disorders

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1816557A (zh) * 2003-05-13 2006-08-09 葛兰素集团有限公司 新型14和15元环化合物
CN1820017A (zh) * 2003-05-13 2006-08-16 葛兰素集团有限公司 4"位取代的大环内酯类
CN1852912A (zh) * 2003-05-13 2006-10-25 葛兰素集团有限公司 新型14和15元环化合物
CN1837225A (zh) * 2005-08-23 2006-09-27 济南思创生物技术有限公司 阿奇霉素衍生物及其制法和药物应用
US20130045938A1 (en) * 2010-02-15 2013-02-21 Synovo Gmbh Kinase modulators for the treatment of cancer
WO2013003731A2 (en) * 2011-06-29 2013-01-03 Insite Vision Incorporated Methods of treating recurrent meibomian glands disorder and thereby decreasing the frequency of recurrence
WO2018161039A1 (en) * 2017-03-03 2018-09-07 Synovo Gmbh Novel anti-infective and anti-inflammatory compounds
WO2018215638A1 (en) * 2017-05-26 2018-11-29 Novaliq Gmbh Pharmaceutical compositions comprising azithromycin

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JING QIAO 等: "E merging treatment options for meibomian gland dysfunction", 《CLINICAL OPHTHALMOLOGY》, vol. 7, pages 1797 - 1803 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116940570A (zh) * 2020-10-21 2023-10-24 阿祖拉眼科有限公司 用于治疗眼部病症的化合物和方法

Also Published As

Publication number Publication date
WO2020212760A3 (en) 2021-02-25
CA3136369A1 (en) 2020-10-22
IL287280A (en) 2021-12-01
WO2020212760A2 (en) 2020-10-22
EP3955937A4 (en) 2023-01-18
JP2022529315A (ja) 2022-06-21
US20230348517A1 (en) 2023-11-02
US20210230205A1 (en) 2021-07-29
AU2020259997A1 (en) 2021-11-25
JP2026102607A (ja) 2026-06-23
JP7904691B2 (ja) 2026-08-13
AU2020259997B2 (en) 2025-08-07
KR20210154214A (ko) 2021-12-20
US11643429B2 (en) 2023-05-09
EP3955937A2 (en) 2022-02-23

Similar Documents

Publication Publication Date Title
AU2020259997B2 (en) Compounds and methods for the treatment of ocular disorders
JP7700045B2 (ja) 眼障害を処置するための化合物および方法
AU2021363702A1 (en) Compounds and methods for the treatment of ocular disorders
KR20230110514A (ko) 안구 장애의 치료를 위한 화합물 및 방법
CN116635032A (zh) 用于治疗眼部病症的化合物和方法
US20250042931A1 (en) Compounds and methods for the treatment of ocular disorders
JP2025542255A (ja) 皮膚および眼の障害を処置するための化合物および方法
JP2024538954A (ja) 皮膚および眼の障害を処置するための化合物および方法
HK40068817A (en) Compounds and methods for the treatment of ocular disorders
HK40068671A (en) Compounds and methods for the treatment of ocular disorders
CN116940570A (zh) 用于治疗眼部病症的化合物和方法
HK40102653A (en) Compounds and methods for the treatment of ocular disorders
HK40100091A (en) Compounds and methods for the treatment of ocular disorders

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40068817

Country of ref document: HK